0000899243-21-018121.txt : 20210504 0000899243-21-018121.hdr.sgml : 20210504 20210504163102 ACCESSION NUMBER: 0000899243-21-018121 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210504 FILED AS OF DATE: 20210504 DATE AS OF CHANGE: 20210504 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arkin Moshe CENTRAL INDEX KEY: 0001321178 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40366 FILM NUMBER: 21889005 MAIL ADDRESS: STREET 1: 6 HACHOSHLIM ST. CITY: HERZELIA STATE: L3 ZIP: 4672406 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arkin Bio Ventures GPGP Ltd. CENTRAL INDEX KEY: 0001858707 STATE OF INCORPORATION: L3 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40366 FILM NUMBER: 21889006 BUSINESS ADDRESS: STREET 1: 6 HA CHOSHLIM ST. STREET 2: BUILDING C, 6TH FLOOR CITY: HERZLIYA STATE: L3 ZIP: 4672406 BUSINESS PHONE: 972-97883330 MAIL ADDRESS: STREET 1: 6 HA CHOSHLIM ST. STREET 2: BUILDING C, 6TH FLOOR CITY: HERZLIYA STATE: L3 ZIP: 4672406 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arkin Bio Ventures 2 L.P. CENTRAL INDEX KEY: 0001858705 STATE OF INCORPORATION: L3 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40366 FILM NUMBER: 21889007 BUSINESS ADDRESS: STREET 1: 6 HA CHOSHLIM ST. STREET 2: BUILDING C, 6TH FLOOR CITY: HERZLIYA STATE: L3 ZIP: 4672406 BUSINESS PHONE: 972-97883330 MAIL ADDRESS: STREET 1: 6 HA CHOSHLIM ST. STREET 2: BUILDING C, 6TH FLOOR CITY: HERZLIYA STATE: L3 ZIP: 4672406 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Werewolf Therapeutics, Inc. CENTRAL INDEX KEY: 0001785530 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 823523180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1030 MASSACHUSETTS AVENUE STREET 2: SUITE 210 CITY: CAMBRIDGE STATE: MA ZIP: 02138 BUSINESS PHONE: 617-952-0555 MAIL ADDRESS: STREET 1: 1030 MASSACHUSETTS AVENUE STREET 2: SUITE 210 CITY: CAMBRIDGE STATE: MA ZIP: 02138 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-05-04 1 0001785530 Werewolf Therapeutics, Inc. HOWL 0001858705 Arkin Bio Ventures 2 L.P. 6 HACHOSHLIM STREET HERZLIYA PITUACH L3 4672406 ISRAEL 0 0 1 0 0001858707 Arkin Bio Ventures GPGP Ltd. 6 HACHOSHLIM STREET BUILDING C HERZLIYA PITUACH L3 4672406 ISRAEL 0 0 1 0 0001321178 Arkin Moshe 6 HACHOSHLIM ST. HERZELIA L3 4672406 ISRAEL 0 0 1 0 Common Stock 2021-05-04 4 C 0 1235917 A 1235917 I See footnote Common Stock 2021-05-04 4 C 0 410717 A 1646634 I See footnote Common Stock 2021-05-04 4 P 0 400000 16.00 A 2046634 I See footnote Series A Preferred Stock 2021-05-04 4 C 0 10714284 0.00 D Common Stock 1235917 0 I See footnote Series B Preferred Stock 2021-05-04 4 C 0 3560551 0.00 D Common Stock 410717 0 I See footnote On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund. On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. This Form 4 shall not be construed as an admission by any of the Reporting Persons or any other entity named in this Form 4 that it is the beneficial owner of any of the securities covered by this Form 4, and each such Reporting Person or entity disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein. Arkin Bio Ventures 2 L.P., By: Its ultimate General Partner, Arkin Bio Ventures GPGP Ltd., By: Its sole shareholder and Chairman of the Board, Moshe Arkin, By: /s/ Yair Ben Yosef, attorney-in-fact 2021-05-04 Arkin Bio Ventures GPGP Ltd., By: Its sole shareholder and Chairman of the Board, Moshe Arkin, By: /s/ Yair Ben Yosef, attorney-in-fact 2021-05-04 Moshe Arkin, By: /s/ Yair Ben Yosef, attorney-in-fact 2021-05-04